<DOC>
	<DOCNO>NCT01463982</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) Oratecan combination capecitabine</brief_summary>
	<brief_title>Phase I OratecanTM Combination With Capecitabine Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description>Besides main objective , 4 objective follow : - To assess safety Oratecan combination capecitabine - To evaluate anticancer activity Oratecan combination capecitabine patient advance solid malignancy - To characterize pharmacokinetics Oratecan metabolite follow oral administration OratecanTM combination capecitabine</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor Patients experience progressive disease despite conventional anticancer therapy . Patients expect effective treatment prolong survival conventional anticancer therapy Previous chemotherapy , radiotherapy surgical operation allow discontinue least 4 week prior D0 adverse event resolve Aged â‰¥19 Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 A life expectancy great 12 week Adequate bone marrow , renal liver function . Subjects must provide write informed consent prior performance study specific procedure assessment , must willing comply treatment follow assessment procedures Patients hematopoietic malignancy , uncontrolled infection , CNS metastasis . Patients undergone hematopoietic stem cell transplantation ( HSCT ) candidate plan HSCT Patients GI malabsorption difficulty take oral medication Patients psychiatric congenital disorder Subjects , investigator 's opinion , treat per protocol due functional impairment Pregnant breastfeeding patient ; Women childbearing potential without adequate contraception ( Men must use adequate contraception . )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Advanced solid cancer</keyword>
</DOC>